January 20, 2021
UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
July 26, 2023
UC San Diego Health is among the first in the nation to perform an experimental regenerative brain cell therapy for epilepsy aimed at eliminating seizures.
October 11, 2016
Professor of Cellular and Molecular Medicine Pradipta Ghosh, second guest in the series, will address “The Herculean Task of Killing Cancer Cells: Spare the Heads of Hydra; Strike the Heart,” at 4 p.m. on Tuesday, October 18, in the Roth Auditorium at the Sanford Consortium for Regenerative Medicine.
October 16, 2023
Researchers from University of California San Diego have identified a new biomarker that can predict whether or not neurons will regenerate after an injury. The findings could help scientists develop regenerative therapies for spinal cord injuries and other neurological conditions.
December 21, 2021
Researchers at the University of California San Diego launched blood stem cells into space aboard a SpaceX Falcon 9 rocket to study stress-induced aging and how stem cells and their progeny transform into pre-cancer and cancer stem cells associated with leukemia and other blood cancers.
November 20, 2014
While investigating a rare genetic disorder, researchers at the University of California, San Diego School of Medicine have discovered that a ubiquitous signaling molecule is crucial to cellular reprogramming, a finding with significant implications for stem cell-based regenerative medicine, wound repair therapies and potential cancer treatments.
December 16, 2016
…applications for the study of cancers, wound healing and regenerative medicine.
December 1, 2022
The California Institute for Regenerative Medicine has awarded UC San Diego researchers $4.8 million to advance a gene therapy to treat Friedreich’s ataxia, a rare but devastating neuromuscular disorder.
January 13, 2014
In a paper published in this week’s Online Early Edition of PNAS, researchers from the University of California, San Diego School of Medicine identify a key gene receptor and signaling pathway essential to maintaining hESCs in an undifferentiated state.
September 16, 2014
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
